Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(3 sites)

United States

University of California, Irvine, Irvine, California

University of California Davis Comprehensive Cancer Center, Sacramento, California

University of California, San Francisco, San Francisco, California